Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01574326 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT01574326 is a Phase 2 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 101 participants.
The verdict
NCT01574326, a Phase 2 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
Objective: In hyperphosphatemic pediatric participants with chronic kidney disease (CKD) to * Evaluate the safety and tolerability of sevelamer carbonate * Evaluate the efficacy of sevelamer carbonate on the control of serum phosphorus
Interventions
- DRUG Placebo
- DRUG Sevelamer carbonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2012-05 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01574326
The ClinicalTrials.gov registry entry for NCT01574326 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01574326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01574326 about?
NCT01574326 is a clinical study titled "An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease". Objective: In hyperphosphatemic pediatric participants with chronic kidney disease (CKD) to * Evaluate the safety and tolerability of sevelamer carbonate * Evaluate the efficacy of sevelamer carbonate on the control of serum phosphorus
What is the current status of trial NCT01574326?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2012-05. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01574326?
The interventions under investigation include: Placebo (DRUG), Sevelamer carbonate (DRUG).
Who is sponsoring clinical trial NCT01574326?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.